<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122754</url>
  </required_header>
  <id_info>
    <org_study_id>B/F/TAF</org_study_id>
    <nct_id>NCT05122754</nct_id>
  </id_info>
  <brief_title>Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 Infection</brief_title>
  <official_title>Switching From Tenofovir Disoproxil Fumarate-based Antiretroviral Therapy Regimens to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virally Suppressed Adults With HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xixi Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yunnan AIDS Care Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus&#xD;
      tenofovir disoproxil fumarate-based antiretroviral regimens in HIV-infected individuals with&#xD;
      virological suppression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, randomized, controlled, open labeled clinical trial, which aims&#xD;
      to evaluate the safety and efficacy of B/F/TAF versus TDF-based antiretroviral therapy in&#xD;
      HIV-infected individuals with virological suppression, and to evaluate the changes in quality&#xD;
      of life and adherence after switching from a TDF-based regimen to B/F/TAF in HIV-infected&#xD;
      individuals with virological suppression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">April 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change from baseline in spine and hip bone mineral density (DXA) at 48 weeks</measure>
    <time_frame>From baseline to Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in spine and hip bone mineral density (DXA) at Week 24</measure>
    <time_frame>From baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with spine or hip bone mineral density (DXA) that increased or decreased by more than 3% (not included) from baseline at Weeks 24 and 48</measure>
    <time_frame>From baseline to Week 24, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Spine and Hip Bone Mineral Density T-Values (DXA) at Weeks 24 and 48</measure>
    <time_frame>From baseline to Week 24, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in eGFR at Weeks 24 and 48 (CKD-EPI Formula)</measure>
    <time_frame>From baseline to Week 24, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with HIV viral load &lt; 50 copies /ml at Weeks 24 and 48</measure>
    <time_frame>From baseline to Week 24, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in CD4 T cell count at Weeks 24 and 48</measure>
    <time_frame>From baseline to Week 24, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in CD4/CD8 ratio at Weeks 24 and 48</measure>
    <time_frame>From baseline to Week 24, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in blood lipid (TC, TG, LDL, HDL) at Weeks 24 and 48</measure>
    <time_frame>From baseline to Week 24, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score (WHO QOL-BREF-HIV Scale) change from baseline at Weeks 24 and 48</measure>
    <time_frame>From baseline to Week 24, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence (Visual Analog Scale) change from baseline at Weeks 24 and 48</measure>
    <time_frame>From baseline to Week 24, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients reported outcome using SSC-HIV-SC scale</measure>
    <time_frame>From baseline to Week 24, 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>B/F/TAF group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bictegravir/emtricitabine/tenofovir alafenamide for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDF-based triple ART regimen switching to B/F/TAF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TDF-based triple ART regimen for 24 weeks, and all switch to bictegravir/emtricitabine/tenofovir alafenamide for the later 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B/F/TAF</intervention_name>
    <description>Bictegravir/emtricitabine/tenofovir alafenamide once daily, 1 tablet at a time, with or without food for 48 weeks.</description>
    <arm_group_label>B/F/TAF group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF-based triple ART regimen switching to B/F/TAF</intervention_name>
    <description>Tenofovir disoproxil fumarate was administered once daily, one tablet at a time, with or without food. After Week 24, control subjects were also switched to bictegravir/emtricitabine/tenofovir alafenamide once daily, one tablet at a time, with or without food for the later 24 weeks.</description>
    <arm_group_label>TDF-based triple ART regimen switching to B/F/TAF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet the Diagnostic Criteria for AIDS or HIV Infection (WS 293-2019);&#xD;
&#xD;
          -  Age 18 or above (included 18);&#xD;
&#xD;
          -  Continuous administration of a TDF-based triple ART regimen with a backbone of&#xD;
             non-nucleoside reverse transcriptase or protease inhibitors ≥24 weeks and ongoing use;&#xD;
&#xD;
          -  Maintaining virological suppression (viral load &lt; 50 copies/mL) for ≥ 24 weeks, and&#xD;
             maintaining virological suppression at present;&#xD;
&#xD;
          -  Glomerular filtration rate (eGFR) ≥ 50 mL/min/1.73 m2 (calculated according to the&#xD;
             CKD-EPI formula);&#xD;
&#xD;
          -  ECG is normal;&#xD;
&#xD;
          -  White blood cell count ≥3×109/L, Neutrophil count ≥1.5×109/L, Hemoglobin ≥90 g/L, and&#xD;
             Platelet count ≥ 75×109/L;&#xD;
&#xD;
          -  Alanine aminotransferase and aspartate aminotransferase ≤5×ULN, direct bilirubin&#xD;
             ≤1.5×ULN, amylase≤2×ULN；&#xD;
&#xD;
          -  Those who volunteered for this study and were able to complete all follow-up visits&#xD;
             and sign the informed consent form in accordance with the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In the 30 days(inclusive) before the screening period, an AIDS-related opportunistic&#xD;
             infection or tumor occurred;&#xD;
&#xD;
          -  History of known past HIV resistance (confirmed HIV viral load &gt; 200 copies /ml) or&#xD;
             resistance to any nucleoside (acid) analogues;&#xD;
&#xD;
          -  Decompensated liver cirrhosis;&#xD;
&#xD;
          -  Female subject who has a positive urine pregnancy test;&#xD;
&#xD;
          -  Lactating women;&#xD;
&#xD;
          -  Women who are unable to take a reasonable method of contraception during the trial&#xD;
             (including the Screening Period and 30 days after discontinuation of experimental&#xD;
             drugs);&#xD;
&#xD;
          -  Subjects had other medical conditions requiring treatment with either of the current&#xD;
             ART regimens or other drugs which have drug-drug interaction with B/F/TAF and cannot&#xD;
             be discontinued.&#xD;
&#xD;
          -  Being involved in other interventional clinical studies;&#xD;
&#xD;
          -  Those with allergic constitution or known allergy to the components of the drug;&#xD;
&#xD;
          -  Suffering from serious mental or neurological diseases;&#xD;
&#xD;
          -  Suspected or confirmed history of alcohol and drug abuse; Patients who were not&#xD;
             considered by the investigator to be suitable for participating in this clinical trial&#xD;
             (such as weak constitution, poor compliance, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Chen, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Public Health Clinical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Chen, M.D</last_name>
    <phone>021-37990333</phone>
    <phone_ext>3222</phone_ext>
    <email>qtchenjun@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jun Chen, M.D</last_name>
      <phone>+86-021-37990333</phone>
      <phone_ext>3222</phone_ext>
      <email>qtchenjun@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yunnan AIDS Care Center</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xicheng Wang</last_name>
    </contact>
    <investigator>
      <last_name>Xicheng Wang, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xixi hospital of Hangzhou</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianhua Yu, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Jianhua Yu, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Jun Chen, MD</investigator_full_name>
    <investigator_title>Deputy Director of Department of Infectious Diseases and Immunology</investigator_title>
  </responsible_party>
  <keyword>Bictegravir/Emtricitabine/Tenofovir alafenamide</keyword>
  <keyword>Tenofovir Disoproxil Fumarate</keyword>
  <keyword>HIV-1 infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

